Funda Meric-Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily pretreated locally advanced or metastatic urothelial cancer.
Videos
Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ciltacabtagene autoleucel (cilta-cel) compared with standard treatment options in relapsed/refractory multiple myeloma (R/R MM) patients who received 1 to 3 prior lines of therapy.
Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers, and coordination of care to optimize real-world outcomes.
An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate cancer, such as abiraterone (ABI) based on COU-AA-301 and enzalutamide (ENZA) based on AFFIRM.
A panelist discusses how second-line treatment options for kidney cancer have evolved through multiple clinical trials including Study 205, METEOR, CONTACT-03, TIVO-3, TiNivo-2, and LITESPARK-005, which have demonstrated varying efficacy across different patient populations and prior therapies, particularly noting the impact of prior immunotherapy exposure on treatment selection and the need for careful consideration of historical trial data in the context of modern treatment paradigms.
An expert discusses the case of a patient with metastatic castration-resistant prostate cancer (CRPC) who progressed after treatment with androgen receptor pathway inhibitors (ARPI) and docetaxel for localized prostate cancer.
The panelist discusses how, Healthcare professionals manage distinct toxicities with ami+laz (IRRs, rash) and osi+chemotherapyctx (cytopenias, diarrhea, fatigue). SKIPPirr informs IRR mitigation in ami’s first infusion. Proactive AE strategies include premedication, dose adjustments, supportive care, and monitoring.
The panelist discusses how, regarding the patient case, she will review the FDA approved options for the patient, including the combination of amivantamab + Lazertinib, osimertinib/chemotherapy, or single agent osimertinib.
A panelist discusses how second-line therapy goals typically shift from pursuing complete remission (as in first-line treatment) to focusing more on disease control, quality of life management, and balancing treatment effectiveness with tolerability based on the patient's prior therapy experience.
Shilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community oncologists.
Panelists discuss first-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on the selection of targeted therapies and factors influencing clinical choices.
Panelists discuss the use of RNA-based molecular panels in metastatic non–-small cell lung cancer (NSCLC), highlighting their role in guiding personalized treatment decisions and improving patient outcomes.
Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.
Olalekan O Oluwole, MD, MBBS, discusses the background and rationale of the research he contributed to, which was presented at the 2025 Transplantation & Cellular Therapy Meetings.
Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.
Panelists discuss how complex cases of advanced myelofibrosis can be managed using evidence-based treatment algorithms, considering factors such as disease progression, prior therapies, and challenging complications.
Panelists discuss how clinicians can effectively manage patients with high-risk myelofibrosis with cytopenias through careful treatment selection, dose modification strategies, and monitoring of hematologic parameters.
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss some specific practices and policies that have been most effective at their institution and how these may be adopted by other practices.
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss how medical mistrust has impacted participation in oncology clinical trials.
Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.
Panelists discuss how to manage an aggressive case of early posttransplant progression in a young woman with functionally high-risk multiple myeloma (MM), focusing on rapid intervention strategies and novel therapeutic approaches to overcome poor prognosis disease.
Panelists discuss how to approach treatment selection and sequencing for a 58-year-old woman with high-risk multiple myeloma (MM) who has developed progressive disease after stem cell transplantation, considering factors such as prior therapy exposure, available options, and disease biology.
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss potential strategies that teams can implement to ensure clinical trials are more representative of the general population.
Panelists discuss decision-making in metastatic non–-small cell lung cancer (NSCLC) when molecular testing results are delayed, focusing on strategies to optimize treatment while awaiting results.
Panelists discuss the role of molecular testing in metastatic non–-small cell lung cancer (NSCLC), emphasizing its importance in identifying actionable mutations and guiding personalized treatment strategies.
Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma therapy.
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss which populations are seen as the most underrepresented in oncology clinical trials.
Saeed Sadeghi, MD, discusses treatment options in low-risk myelodysplastic syndrome at a Case-Based Roundtable event.
Noah S. Kalman, MD, MBA, discusses the evolving role of molecular and genetic testing in thyroid cancer management.